Michael Barbella, Managing Editor02.11.21
HORIBA Ltd. and HORIBA Instruments are expanding their footprint in the in-vitro diagnostic and laboratory chemical sectors.
HORIBA (based in Kyoto, Japan) and HORIBA Instruments (headquartered in Irvine, Calif.) have acquired MedTest Holdings Inc., based in Canton, Mich., and comprised of MedTest Dx Inc., Pointe Scientific Inc., Clinitox Diagnostix Inc., and Medical Laboratory Solutions Inc.
"Our long-term vision and continuous investments coupled with our outstanding employees have resulted in pursuing innovative chemistry and immunochemistry technology solutions. I am extremely pleased that this long term vision has resulted in acquiring MedTest," said Atsushi Horiba, chairman and group CEO of HORIBA Ltd.
The acquisition will combine the complimentary innovative technology offerings of the HORIBA Medical segment (referred to as HORIBA Medical) with MedTest Dx technology, Clinitox, and Pointe Scientific's R&D and manufacturing capabilities, with particular expertise in U.S. Food and Drug Administration 510(k) and CLIA clearances, to address the multidisciplinary requirements of IVD1 testing customers.
"This acquisition provides HORIBA Medical the opportunity to address the IVD market's multidisciplinary requirements along with the complimentary innovative technology of Pointe Scientific and MedTest's chemistry solutions. HORIBA Medical will continue offering innovative technology solutions through its Yumizen2 brand and current distribution channels," said HORIBA Medical segment leader Dr. Jai Hakhu, chairman and CEO of HORIBA Instruments Inc. and president of HORIBA ABX SAS in France.
HORIBA Medical will continue investing in innovative technologies for future IVD requirements.
HORIBA Medical provides a line of hematology and clinical chemistry analyzers (including reagents) for use in in-vitro diagnostics. MedTest Dx is a world Leader in chemistry reagents manufacturing and diagnostic solutions for decentralized clinical testing, providing a combination of screening instruments and reagent manufacturing in medical technologies, with a wide portfolio of products for IVD testing laboratories.
References
1 IVD (In-vitro Diagnostics): The laboratory analysis of body substances (e.g., blood, saliva, stool, or urine) for specific analyses indicative of disease.
2 Yumizen brand: Please refer to the web site. http://www.horiba.com/us/en/medical/yumizen/
HORIBA (based in Kyoto, Japan) and HORIBA Instruments (headquartered in Irvine, Calif.) have acquired MedTest Holdings Inc., based in Canton, Mich., and comprised of MedTest Dx Inc., Pointe Scientific Inc., Clinitox Diagnostix Inc., and Medical Laboratory Solutions Inc.
"Our long-term vision and continuous investments coupled with our outstanding employees have resulted in pursuing innovative chemistry and immunochemistry technology solutions. I am extremely pleased that this long term vision has resulted in acquiring MedTest," said Atsushi Horiba, chairman and group CEO of HORIBA Ltd.
The acquisition will combine the complimentary innovative technology offerings of the HORIBA Medical segment (referred to as HORIBA Medical) with MedTest Dx technology, Clinitox, and Pointe Scientific's R&D and manufacturing capabilities, with particular expertise in U.S. Food and Drug Administration 510(k) and CLIA clearances, to address the multidisciplinary requirements of IVD1 testing customers.
"This acquisition provides HORIBA Medical the opportunity to address the IVD market's multidisciplinary requirements along with the complimentary innovative technology of Pointe Scientific and MedTest's chemistry solutions. HORIBA Medical will continue offering innovative technology solutions through its Yumizen2 brand and current distribution channels," said HORIBA Medical segment leader Dr. Jai Hakhu, chairman and CEO of HORIBA Instruments Inc. and president of HORIBA ABX SAS in France.
HORIBA Medical will continue investing in innovative technologies for future IVD requirements.
HORIBA Medical provides a line of hematology and clinical chemistry analyzers (including reagents) for use in in-vitro diagnostics. MedTest Dx is a world Leader in chemistry reagents manufacturing and diagnostic solutions for decentralized clinical testing, providing a combination of screening instruments and reagent manufacturing in medical technologies, with a wide portfolio of products for IVD testing laboratories.
References
1 IVD (In-vitro Diagnostics): The laboratory analysis of body substances (e.g., blood, saliva, stool, or urine) for specific analyses indicative of disease.
2 Yumizen brand: Please refer to the web site. http://www.horiba.com/us/en/medical/yumizen/